Roche reports positive results for its experimental lung cancer drug divarasib, presenting what multiple outlets describe as standout trial data. The findings come from a pivotal phase III study, highlighted at ESMO, where analysts and healthcare observers focus on the measured benefits compared with other KRAS-targeted therapies.
Quartz emphasizes that median overall survival was reported as 17.7 months for divarasib versus 12.0 months for sotorasib or adagrasib, citing a 338-patient trial. STAT similarly frames the ESMO dataset as particularly impressive, characterising divarasib as delivering a “lung cancer win” within the competitive KRAS-drug landscape. Taken together, the coverage centers on clinical performance signals and the competitive comparisons that would position Roche’s candidate against related rivals.
With only two sources provided, both outlets align on the core message: Roche’s divarasib shows favorable outcomes in a pivotal study presented at ESMO, and the reporting underscores comparative effectiveness against competing KRAS inhibitors.